Aligos director granted 5,860 stock options
Aligos Therapeutics director Heather Preston received a new stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aligos Therapeutics director Heather Preston received a new stock option grant. The award covers 5,860 shares of common stock with an exercise price of $5.50 per share and expires on June 25, 2036.
The option will vest and become exercisable in full on the earlier of the first anniversary of the June 25, 2026 grant date or immediately prior to the company’s 2027 annual stockholder meeting, provided she continues serving the company through that date.
Insider Trade Summary
Grant/Award: 5,860 shares
Grant/Award
1 txn
Insider
Preston Heather
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,860 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,860 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
Key Figures
Option grant size: 5,860 options
Exercise price: $5.50 per share
Expiration date: June 25, 2036
+2 more
5 metrics
Option grant size
5,860 options
Stock Option (Right to Buy) granted June 25, 2026
Exercise price
$5.50 per share
Strike price of granted stock options
Expiration date
June 25, 2036
Option term for 5,860-share grant
Underlying shares
5,860 shares
Common stock underlying the option
Post-transaction derivative holdings
5,860 options
Total derivative securities held after grant
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, continuous service, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 5.5000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-25T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
continuous service financial
"subject to continuous service to the Issuer through such vesting date"
annual meeting financial
"immediately prior to the annual meeting in 2027 of the Issuer's stockholders"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Heather Preston report in the latest Aligos Therapeutics (ALGS) Form 4?
Heather Preston reported receiving a stock option grant for 5,860 shares of Aligos Therapeutics common stock. The option is compensation-related, carries a $5.50 exercise price per share, and expires on June 25, 2036, according to the Form 4 disclosure.
Is the Heather Preston Form 4 for Aligos Therapeutics (ALGS) a purchase or a grant?
The Form 4 reflects a grant, not an open-market purchase. Preston received 5,860 stock options as a compensation award with a $5.50 exercise price, classified under transaction code A for grant, award, or other acquisition in the SEC filing.
When do Heather Preston’s Aligos Therapeutics (ALGS) options vest?
The options vest 100% on the earlier of the first anniversary of the June 25, 2026 grant date or immediately before Aligos Therapeutics’ 2027 annual stockholder meeting. Vesting is contingent on her continuous service to the company through the applicable vesting date.
What is the exercise price and expiration for Heather Preston’s ALGS stock options?
The granted stock options have a $5.50 exercise price per share and expire on June 25, 2036. This gives Heather Preston the right to buy 5,860 Aligos Therapeutics common shares at that fixed price until the expiration date.
How many Aligos Therapeutics (ALGS) derivative securities does Heather Preston hold after this Form 4?
After the reported transaction, Heather Preston holds 5,860 stock options as shown in the Form 4. These options each relate to one share of Aligos Therapeutics common stock and represent her recorded derivative position following the grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
